摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(quinolin-3-ylamino)-isonicotinic acid | 1258420-61-9

中文名称
——
中文别名
——
英文名称
2-(quinolin-3-ylamino)-isonicotinic acid
英文别名
2-[(Quinolin-3-yl)amino]isonicotinic acid;2-(quinolin-3-ylamino)pyridine-4-carboxylic acid
2-(quinolin-3-ylamino)-isonicotinic acid化学式
CAS
1258420-61-9
化学式
C15H11N3O2
mdl
——
分子量
265.271
InChiKey
PLFPWCLLFOJLBI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    75.1
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • [EN] BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES<br/>[FR] COMPOSÉS BICYCLIQUES UTILES POUR LE TRAITEMENT DE MALADIES CAUSÉES PAR DES RÉTROVIRUS
    申请人:SPLICOS
    公开号:WO2015001518A1
    公开(公告)日:2015-01-08
    Described herein are methods for preventing or treating a retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection. In certain aspects, the methods described herein include contacting a cell in need thereof with compound (I), wherein (II) means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a –CN group, a hydroxyl group, a –COOR1 group, a (C1 -C3)fluoroalkyl group, a (C1 -C3)fluoroalkoxy group, a –NO2 group, a –NR1R2 group, a (C1-C4)alkoxy group, a phenoxy group and a (C1-C3)alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n' is 1 or 2, R' is a hydrogen atom, a halogen atom or a group chosen among a (C1-C3)alkyl group,, a hydroxyl group, a –COOR1 group, a –NO2 group, a –NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a (C1-C4)alkoxy group and a –CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, to prevent or treat the retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection, wherein the retroviral infection is not HIV and the disease caused by the retroviral infection is not AIDS.
    本文描述了一种预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病的方法。在某些方面,所述方法包括将化合物(I)与需要其治疗的细胞接触,其中(II)表示吡啶嗪、嘧啶吡嗪基团,R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)代烷基团、(C1-C3)代烷氧基团、-NO2基团、-NR1R2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团,所述烷基可以选择性地被羟基基团单取代,n为1、2或3,n'为1或2,R'为氢原子、卤素原子或在(C1-C3)烷基团、羟基基团、-COOR1基团、- 基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(C1-C3)代烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团,Z为N或C,Y为N或C,X为N或C,W为N或C,T为N或C,U为N或C,以预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病,其中逆转录病毒感染不是HIV,由逆转录病毒感染引起的疾病不是艾滋病。
  • COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA
    申请人:Tazi Jamal
    公开号:US20120329796A1
    公开(公告)日:2012-12-27
    The present invention relates to compound (I) wherein: means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO2 group, a —NRiR2 group, a (C 1 -C 4 )alkoxy group, a phenoxy group and a (C 1 -C 3 )alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n′ is 1 or 2, R′ is a hydrogen atom, a halogen atom or a group chosen among a (Ci-C3)alkyl group, a hydroxyl group, a —COOR 1 group, a —NO2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (Ci-C3)fluoroalkyl group, a (C 1 -C 4 )alkoxy group and a —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging. Some of said compounds are new and also form part of the invention.
    本发明涉及化合物(I),其中:表示吡啶嗪、嘧啶吡嗪基团,R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)氟烷基团、(C1-C3)氟烷氧基团、-NO2基团、-NRiR2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团,所述烷基可以选择性地被一个羟基基团单取代,n为1、2或3,n'为1或2,R'为氢原子、卤素原子或在(Ci-C3)烷基团、羟基基团、-COOR1基团、- 基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(Ci-C3)氟烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团,Z为N或C,Y为N或C,X为N或C,W为N或C,T为N或C,U为N或C,用作预防、抑制或治疗与早衰有关的病理或非病理状态的药剂。其中一些化合物是新的,也是本发明的一部分。
  • Compounds useful to treat premature aging and in particular progeria
    申请人:Splicos Sas
    公开号:EP2261214A1
    公开(公告)日:2010-12-15
    The present invention relates to a compound of formula (I): wherein: means an aromatic ring wherein V is C or N and when V is N, V is in ortho, meta or para of Z, i.e. forms respectively a pyridazine, a pyrimidine or a pyrazine group, R independently represents a hydrogen atom, a halogen atom or a group chosen among a (C1-C3)alkyl group, a -CN group, a -COOH group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group, a -NO2 group, a -NR1R2 group and a (C1-C3)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, n is 1 or 2, R' is a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxy group, a -COOH group and a -CN group, R" is a hydrogen atom or a (C1-C4)alkyl group, Z is N or C, Y is N or C, X is N or C, W is N or C, and wherein at most two of the groups Z, Y, X and W are N, or anyone of its pharmaceutically acceptable salt, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
    本发明涉及一种式 (I) 的化合物: 其中 指一个芳香环,其中 V 是 C 或 N,当 V 是 N 时,V 位于 Z 的正位、偏位或对位,即分别形成哒嗪嘧啶吡嗪基团、 R 独立地代表氢原子、卤素原子或选自 (C1-C3) 烷基、-CN 基团、-COOH 基团、(C1-C3) 氟烷基、(C1-C3) 氟烷氧基、-NO2 基团、-NR1R2 基团和 (C1-C3) 烷氧基的基团、 R1 和 R2 独立地为氢原子或 (C1-C3) 烷基、 n 为 1 或 2、 R'是氢原子或选自(C1-C3)烷基、卤素原子、羟基、-COOH 基和-CN 基的基团、 R "是氢原子或 (C1-C4) 烷基、 Z 是 N 或 C、 Y 是 N 或 C X 是 N 或 C W 是 N 或 C、 其中 Z、Y、X 和 W 至多有两个基团是 N、 或其任何一种药学上可接受的盐、 用于预防、抑制或治疗与过早衰老有关的病理或非病理状况。
  • New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
    申请人:Splicos
    公开号:EP2266972A1
    公开(公告)日:2010-12-29
    The present invention relates to a compound of the formula I; a pharmaceutical composition comprising at least one such compound; and the use of such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.
    本发明涉及一种式 I 的化合物;一种包含至少一种此类化合物的药物组合物;以及使用此类化合物制备药物,以治疗受试者因至少一种剪接异常而导致的遗传疾病。
  • Compounds useful for treating AIDS
    申请人:ABIVAX
    公开号:US10017498B2
    公开(公告)日:2018-07-10
    A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NR1R2 group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a phenoxy group, or a (C1-C4)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, or a (C1-C4)alkoxy group, R″ is a hydrogen atom or a (C1-C4)alkyl group, n is 1, 2, or 3, and n′ is 1 or 2.
    具有下式的化合物或其药学上可接受的盐: 其中 R 独立地代表氢原子、卤素原子、(C1-C3)烷基、-NR1R2 基团、(C1-C3)氟烷氧基、-NO2 基团、苯氧基或 (C1-C4)烷氧基、 R1 和 R2 独立地为氢原子或 (C1-C3) 烷基、 R′ 是氢原子、卤素原子、(C1-C3)烷基或(C1-C4)烷氧基、 R″ 是氢原子或 (C1-C4) 烷基、 n 是 1、2 或 3,以及 n′ 为 1 或 2。
查看更多